Zymeworks Inc. Common Stock (ZYME) support and resistance · rev $76.3M
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
This page maps Zymeworks Inc. Common Stock (ZYME) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
ZYME currently screens at market cap $1.68B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new ZYME 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the ZYME quote page for the session range and the stock page for the full model.
Not investment advice.